Developing next-generation mRNA therapeutics for oncology, rare genetic disorders, and infectious diseases through AI-driven design, proprietary delivery systems, and scalable GMP manufacturing.
Our modular platform accelerates discovery-to-delivery with industry-leading safety, stability, and tissue targeting.
Ionizable lipid nanoparticles engineered for enhanced endosomal escape, reduced immunogenicity, and precise organotropism.
Replicon-based constructs enabling lower dose requirements, prolonged protein expression, and enhanced immunogenic profiles.
Surface-conjugated aptamers and glycosylation patterns enabling selective uptake in hepatic, pulmonary, and neuronal tissues.
Lyophilized formulations and stabilized lipid matrices maintaining potency at 2-8°C for 18+ months, enabling global distribution.
Multi-modal candidates advancing through clinical development with a focus on high-unmet-need indications.
| Therapeutic Area | Indication | Phase | Progress | Status |
|---|---|---|---|---|
| OncologyAZ-MR01 | Personalized Neoantigen Vaccine (NSCLC) | Phase III | Enrolling | |
| Infectious DiseaseAZ-MR04 | Broad-Spectrum RSV + Parainfluenza | Phase II | Dosing | |
| Genetic DisordersAZ-MR07 | Spinal Muscular Atrophy (SMA) | Phase I | Recruiting | |
| AutoimmuneAZ-MR12 | Toll-like Receptor Modulator (RA) | Preclinical | \nIND Prep |
Integrated GMP facilities leveraging continuous flow chemistry and AI-optimized batch processing.
Adhering to FDA, EMA, and WHO guidelines with transparent clinical data and rigorous pharmacovigilance.
Explore partnership opportunities, access clinical trial information, or download our latest research brief on next-generation therapeutic platforms.